SCHEMBL1966096

SCHEMBL1966096

CCOC(=O)c1c(O)c2cccn2n(Cc2ccc(OC)cc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 2/20 0.53
KDM4E B2RXH2 8/20 0.48
ALDH1A1 P00352 8/20 0.48
HTT P42858 5/20 0.48
GAA P10253 3/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 3/20 0.44
HPGD P15428 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GLA P06280 2/20 0.44
USP2 O75604 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RECQL P46063 1/20 0.43
LMNA P02545 3/20 0.42
ALOX5 P09917 1/20 0.42
TDP1 Q9NUW8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20654248 0.90 ALDH1A1 (0.56) FEN1KDM4EALDH1A1HTTGAA
SCHEMBL1967127 0.89 KDM4E (0.48) FEN1KDM4EALDH1A1HTTMEN1
SCHEMBL1967350 0.89 KDM4E (0.54) KDM4EALDH1A1HTTGAAMEN1
SCHEMBL1965910 0.88 ALDH1A1 (0.47) FEN1KDM4EALDH1A1HTTGAA
SCHEMBL1968371 0.85 KDM4E (0.47) FEN1KDM4EALDH1A1HTTGAA
SCHEMBL1966099 0.85 KDM4E (0.44) FEN1KDM4EALDH1A1HTTMEN1
SCHEMBL1966103 0.83 KMT2A (0.50) KDM4EALDH1A1MEN1KMT2AMAPK1
SCHEMBL1966018 0.81 LMNA (0.49) FEN1KDM4EALDH1A1HTTGAA
SCHEMBL1965997 0.81 KDM4E (0.50) KDM4EALDH1A1HTTGAAMEN1
SCHEMBL1969506 0.81 HIF1A (0.51) KDM4EHTTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 FEN1 1106/4885KDM4E 471/4885ALDH1A1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.